title: Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes.
abstract: The molecular subtypes of breast cancer have individual patterns of behaviour, prognosis and sensitivity to treatment, with subsequent implications for the choice of, or indeed role for adjuvant therapy. The luminal A and B subtypes make up the majority of breast cancers, but despite sharing expression of the oestrogen receptor (ER), they are molecularly distinct. It follows then that they would have different sensitivities to chemotherapy. Clinically, luminal A disease has a better prognosis than luminal B, and may not derive significant benefit from adjuvant chemotherapy. However no prospective trials have specifically investigated the benefit of adjuvant chemotherapy in each subtype, nor do we know if certain agents are more or less effective. This paper will briefly summarise the role of molecular profiles in assessing the need for chemotherapy and predicting its effectiveness, followed by an assessment of the relative value of newer anthracycline- or taxane-containing regimes in the luminal-like subtypes, providing a review of retrospective analyses.
authors: "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy.
authors: Christopher D
authors: CD
authors: Hart
authors: "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy.
authors: Giuseppina
authors: G
authors: Sanna
authors: "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy.
authors: Olimpia
authors: O
authors: Siclari
authors: "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy.
authors: Laura
authors: L
authors: Biganzoli
authors: "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy. Electronic address: adileo@usl4.toscana.it.
authors: Angelo
authors: A
authors: Di Leo
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000235:genetics*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D011960:Receptors, Estrogen / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics; D013629:Tamoxifen / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D018943:Anthracyclines; D001952:Bridged-Ring Compounds; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D043823:Taxoids; C080625:taxane; C508053:ERBB2 protein, human
keywords: Adjuvant; Breast cancer; Chemotherapy; Luminal; Predicition; Subtype